Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657046 · ClinicalTrials.gov registry record · Phase 2
Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension
A Phase 2 study of Intradialytic Hypotension, sponsored by Chelsea Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 1
- Study location
NCT00657046 is a Phase 2 study of Intradialytic Hypotension that has completed, run by Chelsea Therapeutics. The registered enrollment target is 85 participants, roughly in line with the 79-participant average among 3 other Intradialytic Hypotension trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00657046, a Phase 2 study of Intradialytic Hypotension, has completed, sponsored by Chelsea Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
In clinical trials in Japan, droxidopa has been shown to be effective in affecting blood pressure changes upon orthostatic challenge in patients with autonomic dysfunction, as well as reducing the severity and frequency of symptoms of orthostatic hypotension in these patients. The efficacy of droxidopa in ameliorating symptoms in patients undergoing dialysis has also been demonstrated in the literature and clinical trials conducted in Japan. The current study will investigate the clinical efficacy of two different doses of droxidopa in patients with intradialytic hypotension over a 4 week treatment period with a placebo control. The clinical efficacy will be evaluated by changes in hypotension- related symptoms, as well as changes in blood pressure prior to, during and following, HD sessions as compared to their pre-treatment baseline values.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Droxidopa
Study Locations (1)
Oregon
- Rogue Valley Dialysis - Medford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657046
The ClinicalTrials.gov registry entry for NCT00657046 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 79-participant average among 3 other Intradialytic Hypotension trials with a reported enrollment target. The listed sponsor is Chelsea Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intradialytic Hypotension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00657046 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT00657046 about?
NCT00657046 is a clinical study titled "Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension". In clinical trials in Japan, droxidopa has been shown to be effective in affecting blood pressure changes upon orthostatic challenge in patients with autonomic dysfunction, as well as reducing the severity and frequency of symptoms of orthostatic hypotension in these patients. The efficacy of droxid...
What is the current status of trial NCT00657046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2007-12. Estimated completion is 2009-01.
What conditions does trial NCT00657046 study?
This clinical trial studies the following conditions: Intradialytic Hypotension.
What interventions are being tested in trial NCT00657046?
The interventions under investigation include: Placebo (DRUG), Droxidopa (DRUG).
Who is sponsoring clinical trial NCT00657046?
This trial is sponsored by Chelsea Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00657046 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intradialytic Hypotension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.